Production (Stage)
Inozyme Pharma, Inc.
INZY
$3.98
-$0.01-0.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.39% | -43.35% | -41.55% | -30.42% | -14.10% |
| Total Depreciation and Amortization | -8.91% | -10.92% | -5.84% | -1.99% | 4.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 440.78% | 69.92% | -37.59% | -73.13% | -81.42% |
| Change in Net Operating Assets | 235.37% | 252.95% | 151.37% | 285.48% | -163.92% |
| Cash from Operations | -24.65% | -30.04% | -36.97% | -37.46% | -26.17% |
| Capital Expenditure | 80.65% | 79.19% | 37.24% | 62.01% | 72.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 258.83% | 225.70% | 203.47% | -214.79% | -317.16% |
| Cash from Investing | 258.35% | 224.89% | 202.57% | -200.99% | -301.56% |
| Total Debt Issued | -- | -- | -54.55% | -60.38% | -16.84% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -86.67% | -86.74% | -87.02% | 328.87% | 25.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.19% | -90.95% | -79.15% | 72.77% | 14.45% |
| Foreign Exchange rate Adjustments | 85.19% | 122.22% | 243.43% | -161.90% | -400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.38% | -928.65% | -894.87% | -17.39% | -266.55% |